WO2004058281A1 - Cholesterinsenkendes mittel, enthaltend eine n-3-fettsäure - Google Patents
Cholesterinsenkendes mittel, enthaltend eine n-3-fettsäure Download PDFInfo
- Publication number
- WO2004058281A1 WO2004058281A1 PCT/EP2003/014713 EP0314713W WO2004058281A1 WO 2004058281 A1 WO2004058281 A1 WO 2004058281A1 EP 0314713 W EP0314713 W EP 0314713W WO 2004058281 A1 WO2004058281 A1 WO 2004058281A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cholesterol
- acid
- carob
- lowering
- agent according
- Prior art date
Links
- 235000020660 omega-3 fatty acid Nutrition 0.000 title claims abstract description 56
- 239000003638 chemical reducing agent Substances 0.000 title 1
- 240000008886 Ceratonia siliqua Species 0.000 claims abstract description 59
- 235000013912 Ceratonia siliqua Nutrition 0.000 claims abstract description 59
- 239000000835 fiber Substances 0.000 claims abstract description 38
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims description 40
- 235000013305 food Nutrition 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- 239000003529 anticholesteremic agent Substances 0.000 claims description 10
- 239000003112 inhibitor Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- -1 sterol ester Chemical class 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 229940127226 anticholesterol agent Drugs 0.000 claims description 9
- 238000010521 absorption reaction Methods 0.000 claims description 8
- 239000003613 bile acid Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 8
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 7
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 7
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 7
- 229940068065 phytosterols Drugs 0.000 claims description 7
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 6
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 229940125753 fibrate Drugs 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 235000013311 vegetables Nutrition 0.000 claims description 6
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 5
- 230000001906 cholesterol absorption Effects 0.000 claims description 5
- DTOSIQBPPRVQHS-UHFFFAOYSA-N α-Linolenic acid Chemical compound CCC=CCC=CCC=CCCCCCCCC(O)=O DTOSIQBPPRVQHS-UHFFFAOYSA-N 0.000 claims description 5
- 229930182558 Sterol Natural products 0.000 claims description 4
- 229920000080 bile acid sequestrant Polymers 0.000 claims description 4
- 229940096699 bile acid sequestrants Drugs 0.000 claims description 4
- 235000003702 sterols Nutrition 0.000 claims description 4
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 3
- 229930186217 Glycolipid Natural products 0.000 claims description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- 150000003408 sphingolipids Chemical class 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 claims 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims 1
- AHANXAKGNAKFSK-UHFFFAOYSA-N Bishomo-a-linolenic acid Natural products CCC=CCC=CCC=CCCCCCCCCCC(O)=O AHANXAKGNAKFSK-UHFFFAOYSA-N 0.000 claims 1
- AHANXAKGNAKFSK-PDBXOOCHSA-N all-cis-icosa-11,14,17-trienoic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCCC(O)=O AHANXAKGNAKFSK-PDBXOOCHSA-N 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 abstract description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 68
- 239000000047 product Substances 0.000 description 25
- 230000000694 effects Effects 0.000 description 21
- 235000012000 cholesterol Nutrition 0.000 description 18
- 238000008214 LDL Cholesterol Methods 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 9
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 208000024172 Cardiovascular disease Diseases 0.000 description 8
- 230000009102 absorption Effects 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 235000015872 dietary supplement Nutrition 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 235000013339 cereals Nutrition 0.000 description 5
- 235000012041 food component Nutrition 0.000 description 5
- 239000005428 food component Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 239000000306 component Substances 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 230000008092 positive effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229960004844 lovastatin Drugs 0.000 description 3
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 3
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000001814 pectin Substances 0.000 description 3
- 229920001277 pectin Polymers 0.000 description 3
- 235000010987 pectin Nutrition 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 240000002234 Allium sativum Species 0.000 description 2
- 235000007319 Avena orientalis Nutrition 0.000 description 2
- 244000075850 Avena orientalis Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 244000019459 Cynara cardunculus Species 0.000 description 2
- 235000019106 Cynara scolymus Nutrition 0.000 description 2
- 241000199914 Dinophyceae Species 0.000 description 2
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
- 235000016520 artichoke thistle Nutrition 0.000 description 2
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 2
- 229940085242 benzothiazepine derivative selective calcium channel blockers with direct cardiac effects Drugs 0.000 description 2
- 150000007657 benzothiazepines Chemical class 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000036996 cardiovascular health Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- KZJWDPNRJALLNS-FBZNIEFRSA-N clionasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-FBZNIEFRSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- 229940013317 fish oils Drugs 0.000 description 2
- 235000008410 fruit bars Nutrition 0.000 description 2
- 235000004611 garlic Nutrition 0.000 description 2
- 229960003627 gemfibrozil Drugs 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000012153 long-term therapy Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 229940038580 oat bran Drugs 0.000 description 2
- 229940012843 omega-3 fatty acid Drugs 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 235000002378 plant sterols Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229960002855 simvastatin Drugs 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 2
- 235000009561 snack bars Nutrition 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- VGSSUFQMXBFFTM-UHFFFAOYSA-N (24R)-24-ethyl-5alpha-cholestane-3beta,5,6beta-triol Natural products C1C(O)C2(O)CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 VGSSUFQMXBFFTM-UHFFFAOYSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- LSXZSLZITPNDSA-UHFFFAOYSA-N 1$l^{6}-benzothiepine 1,1-dioxide Chemical class O=S1(=O)C=CC=CC2=CC=CC=C12 LSXZSLZITPNDSA-UHFFFAOYSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- NIGNBCLEMMGDQP-UHFFFAOYSA-N 1-benzothiepine Chemical class S1C=CC=CC2=CC=CC=C12 NIGNBCLEMMGDQP-UHFFFAOYSA-N 0.000 description 1
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 description 1
- ARYTXMNEANMLMU-UHFFFAOYSA-N 24alpha-methylcholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(C)C(C)C)C1(C)CC2 ARYTXMNEANMLMU-UHFFFAOYSA-N 0.000 description 1
- MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- DJQOOSBJCLSSEY-UHFFFAOYSA-N Acipimox Chemical compound CC1=CN=C(C(O)=O)C=[N+]1[O-] DJQOOSBJCLSSEY-UHFFFAOYSA-N 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- OILXMJHPFNGGTO-NRHJOKMGSA-N Brassicasterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@](C)([C@H]([C@@H](/C=C/[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 OILXMJHPFNGGTO-NRHJOKMGSA-N 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 description 1
- BMOVQUBVGICXQN-UHFFFAOYSA-N Clinofibrate Chemical compound C1=CC(OC(C)(CC)C(O)=O)=CC=C1C1(C=2C=CC(OC(C)(CC)C(O)=O)=CC=2)CCCCC1 BMOVQUBVGICXQN-UHFFFAOYSA-N 0.000 description 1
- 229920002911 Colestipol Polymers 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- BDCFUHIWJODVNG-UHFFFAOYSA-N Desmosterol Natural products C1C=C2CC(O)C=CC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 BDCFUHIWJODVNG-UHFFFAOYSA-N 0.000 description 1
- 206010014476 Elevated cholesterol Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000195620 Euglena Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241001491666 Labyrinthulomycetes Species 0.000 description 1
- LNXBEIZREVRNTF-UHFFFAOYSA-N Lifibrol Chemical compound C1=CC(C(C)(C)C)=CC=C1CCC(O)COC1=CC=C(C(O)=O)C=C1 LNXBEIZREVRNTF-UHFFFAOYSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 241000592260 Moritella Species 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 241000224474 Nannochloropsis Species 0.000 description 1
- KUEUWHJGRZKESU-UHFFFAOYSA-N Niceritrol Chemical compound C=1C=CN=CC=1C(=O)OCC(COC(=O)C=1C=NC=CC=1)(COC(=O)C=1C=NC=CC=1)COC(=O)C1=CC=CN=C1 KUEUWHJGRZKESU-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000206731 Phaeodactylum Species 0.000 description 1
- 244000134552 Plantago ovata Species 0.000 description 1
- 235000003421 Plantago ovata Nutrition 0.000 description 1
- HCXVJBMSMIARIN-LWINXXIXSA-N Poriferasterol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C HCXVJBMSMIARIN-LWINXXIXSA-N 0.000 description 1
- 239000009223 Psyllium Substances 0.000 description 1
- 241000233671 Schizochytrium Species 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- 241000863430 Shewanella Species 0.000 description 1
- LGJMUZUPVCAVPU-JFBKYFIKSA-N Sitostanol Natural products O[C@@H]1C[C@H]2[C@@](C)([C@@H]3[C@@H]([C@H]4[C@@](C)([C@@H]([C@@H](CC[C@H](C(C)C)CC)C)CC4)CC3)CC2)CC1 LGJMUZUPVCAVPU-JFBKYFIKSA-N 0.000 description 1
- 241001466451 Stramenopiles Species 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241001467333 Thraustochytriaceae Species 0.000 description 1
- 241000233675 Thraustochytrium Species 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- OILXMJHPFNGGTO-ZRUUVFCLSA-N UNPD197407 Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C=C[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZRUUVFCLSA-N 0.000 description 1
- 241001491678 Ulkenia Species 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 229960003526 acipimox Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical compound O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 229950004495 binifibrate Drugs 0.000 description 1
- BFYRHDVAEJIBON-UHFFFAOYSA-N binifibrate Chemical compound C=1C=CN=CC=1C(=O)OCC(COC(=O)C=1C=NC=CC=1)OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 BFYRHDVAEJIBON-UHFFFAOYSA-N 0.000 description 1
- 230000002210 biocatalytic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- OILXMJHPFNGGTO-ZAUYPBDWSA-N brassicasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZAUYPBDWSA-N 0.000 description 1
- 235000004420 brassicasterol Nutrition 0.000 description 1
- ARYTXMNEANMLMU-ATEDBJNTSA-N campestanol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]2(C)CC1 ARYTXMNEANMLMU-ATEDBJNTSA-N 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002174 ciprofibrate Drugs 0.000 description 1
- KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 description 1
- 229950003072 clinofibrate Drugs 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960002604 colestipol Drugs 0.000 description 1
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- AVSXSVCZWQODGV-DPAQBDIFSA-N desmosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC=C(C)C)C)[C@@]1(C)CC2 AVSXSVCZWQODGV-DPAQBDIFSA-N 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- 229960003501 etofibrate Drugs 0.000 description 1
- XXRVYAFBUDSLJX-UHFFFAOYSA-N etofibrate Chemical compound C=1C=CN=CC=1C(=O)OCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 XXRVYAFBUDSLJX-UHFFFAOYSA-N 0.000 description 1
- 229950009036 etofylline clofibrate Drugs 0.000 description 1
- KYAKGJDISSNVPZ-UHFFFAOYSA-N etofylline clofibrate Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KYAKGJDISSNVPZ-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000021149 fatty food Nutrition 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 235000021197 fiber intake Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000010460 hemp oil Substances 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 235000021192 high fiber diet Nutrition 0.000 description 1
- 230000000871 hypocholesterolemic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 229950000716 lifibrol Drugs 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 1
- 235000021071 low fiber diet Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 229960000827 niceritrol Drugs 0.000 description 1
- 229960004552 nicofuranose Drugs 0.000 description 1
- FUWFSXZKBMCSKF-ZASNTINBSA-N nicofuranose Chemical compound C([C@]1(O)[C@H]([C@H](OC(=O)C=2C=NC=CC=2)[C@@H](COC(=O)C=2C=NC=CC=2)O1)OC(=O)C=1C=NC=CC=1)OC(=O)C1=CC=CN=C1 FUWFSXZKBMCSKF-ZASNTINBSA-N 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000015074 other food component Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229940070687 psyllium Drugs 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- LGJMUZUPVCAVPU-HRJGVYIJSA-N stigmastanol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]2(C)CC1 LGJMUZUPVCAVPU-HRJGVYIJSA-N 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/238—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seeds, e.g. locust bean gum or guar gum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the invention relates to an active ingredient combination for lowering the cholesterol level, comprising at least one cholesterol-lowering carob product, in particular carob fiber, at least one n-3 fatty acid and at least one cholesterol-lowering active ingredient.
- the invention further relates to a process for the preparation of such combinations of active substances and their use.
- the active ingredients can also include cholesterol-lowering agents isolated from plant sources.
- the cholesterol-lowering effect of a group of plant sterols in particular phytosterols, phytostanols and the esters of the classes of compounds mentioned (cf. WO-A-96/38047, WO-A-99/56558, US-A-6,087,353) should be mentioned here in particular.
- the latter in particular are not suitable for consumption for all population groups (e.g. exclusion for pregnant women or small children) and are often restricted in their use.
- Other natural cholesterol-lowering agents also include extracts from other plant sources, such as. B. Artichoke extracts, tocotrienol-rich extracts, garlic or guglipid extracts.
- ß-glucan from oats or barley
- psyllium from psyllium
- pectin from guar gum
- guar gum have a lowering effect on blood cholesterol (Brown et al. 1999; Am. J. Clin. Nutr. 69: 30-42).
- Water-insoluble carob fibers are also known as food components, for example those produced by a process according to EP-A-0616780, which can significantly lower serum cholesterol values, in particular LDL cholesterol (Zunft et al. 2001, Adv. In Ther. 18: 230 -36).
- the HDL value remains constant, so that the important LDL / HDL ratio shifts to "good cholesterol” and thus the risk of arteriosclerosis decreases.
- the clear effect of this insoluble, non-viscous preparation was all the more surprising since such cholesterol reductions generally only occur with viscous, soluble fiber.
- n-3 fatty acids Other food components that can significantly reduce the risk of cardiovascular diseases include n-3 fatty acids. It is known that the supply of n-3 fatty acids is poor in most industrialized nations. In contrast, the total fat content in the diet and the intake of saturated fatty acids and n-6 fatty acids are too high. This is due to a change in the composition of our food, which has mainly taken place in the past approx. 150 years and which varies with the appearance whose chronic (civilization) diseases, especially cardiovascular diseases - the main cause of death in industrialized nations - is correlated.
- n-3 fatty acids appear to have little or no impact on another of the main risk factors, cholesterol levels. At most, a slight shift in the LDL / HDL ratio to "good cholesterol" is discussed (Gylling and Montgomeryn, Curr Control Trials Cardiovasc Med 2001, 123-128).
- a cholesterol-lowering interaction between carob products, n-3 fatty acids and cholesterol-lowering active substances is not known.
- viscous fibers such as pectin with n-3 fatty acids can have a synergistic effect in lowering cholesterol (V. Bartz 2002, Nutrition & Medicine 17, 149-150).
- carob products, especially carob fiber are not viscous, a cholesterol-lowering interaction is not obvious, and certainly not a synergistic one.
- an antagonistic effect of the water-insoluble fibers of the carob pulp with the viscous fiber locust bean gum has been described (Peres-Olleros et al. 1999; J. Sei. Food Agric. 79, 173-178).
- cholesterol-lowering agents e.g. phytosterols
- This object is achieved by providing an active ingredient combination for lowering the cholesterol level, containing at least one carob product, in particular carob fiber, with a high content of fiber, at least one n-3 fatty acid, and at least one cholesterol-lowering active ingredient.
- the active compound combination according to the invention is applied, in addition to the previously described effect of lowering total cholesterol, the ratio of HDL and LDL to the "good" HDL cholesterol shifts.
- an additional positive effect on health is achieved by the dietetic foods according to the invention by means of an increased supply of n-3 fatty acids.
- the DHA which is preferably used according to the invention plays a special role here.
- the active ingredient combination according to the invention can be processed. Balance the body's intake of essential n-3 fatty acids, which experience has shown after fiber administration and in particular as an undesirable side reaction when medication is used to treat high cholesterol levels with statins.
- Locust bean products in the sense of the invention are the locust bean fruit itself and components obtained therefrom.
- locust bean fibers which have a high total fiber content, determined according to AOAC method 985.29, of at least 30% by weight, preferably at least 60% by weight, particularly preferably at least 80% by weight, are preferably used. in relation to the dry matter).
- Their water-insoluble fiber content, determined according to AOAC method 991.42, is at least 25% by weight, preferably at least 50% by weight, particularly preferably at least 70% by weight.
- the carob fiber product For the production of the carob fiber product, it is particularly necessary to separate the water-soluble carob components from the pulp freed from the carob seeds and to heat them for (partial) denaturation of the condensed tannins. Other process steps include washing and separating steps, drying, grinding and, if necessary, screening. Fiber lengths of ⁇ 250 ⁇ m, preferably ⁇ 150 ⁇ m, in particular ⁇ 100 ⁇ m, are obtained.
- the methods according to EP-A-0 616 780 and according to the unpublished PCT / EP03 / 08636 are particularly preferred. The preparations obtained in this way have a pronounced hypocholesterolemic and moderate triglyceride-lowering effect and can be used to fortify foods.
- N-3 fatty acids in the sense of the invention include polyunsaturated long-chain fatty acids (polyunsaturated fatty acids, PUFAs) with a chain length> C1 with at least two double bonds understood, wherein the first of the at least two or more double bonds, starting from the alkyl end, is constituted between the carbon atoms C3 and C4 (see Table 1).
- the n-3 fatty acids can be present as free fatty acids, esters, triglycerides, phospholipids, glycolipids, sphingolipids, waxes or sterol esters or by chemical or biocatalytic transesterification of the triglycerides, for. B.
- n-3 fatty acid or n-3 active ingredients are used synonymously.
- a content of at least 30 area% of TFA is particularly preferred, in particular of at least 40 area% of TFA and very particularly preferably of at least 60 area% of TFA.
- n-3 active ingredients preferably of at least 2 of the n-3 active ingredients DHA, EPA and ALA and particularly preferably a mixture of the n-3 active ingredients DHA and EPA.
- DHA n-3 active ingredients
- EPA or DHA as the main constituent of the n-3 active ingredient is very particularly preferred, in particular the use of DHA as the only n-3 active ingredient.
- a suitable source for one of the above is fish oils.
- a suitable source of ALA are vegetable oils, especially linseed oil or hemp oil and the like. a.
- N-3 active ingredients which are isolated from microorganisms are particularly preferred.
- Preferred microorganisms are organisms of the Stramenopiles (or Labyrinthulomycota), particularly preferably of the order Thraustochytriales (Thraustchytriidea), in particular of the genera Schizochytrium, Thraustochytrium and Ulkenia, and also dinoflagellates (Dinophyta), preferably Crypthecohninium are preferably suitable for the production of DHA with a concentration of at least 20 area% of TFA, preferably of at least 30 area% of TFA and particularly preferably of at least 40 area% of TFA DHA.
- n-3 fatty acids With regard to the production of n-3 fatty acids, reference is made in particular to the following publications: WO-A-91/07498, WO-A-91/11918, WO-A-96/33263 and WO-A-98/03671 ,
- Additional sources for EPA and / or DHA are e.g. B. also microalgae such as Euglena (JP-A 60-196157), Nannochloropsis, Phaeodactylum and others (Tonon et al., Long chain polyunsaturated fatty acid production and partitioning to triacylglycerols in four microalgae. Phytochemistry 2002, 15-24), but also Bacteria, preferably z. B.
- microalgae such as Euglena (JP-A 60-196157), Nannochloropsis, Phaeodactylum and others (Tonon et al., Long chain polyunsaturated fatty acid production and partitioning to triacylglycerols in four microalgae. Phytochemistry 2002, 15-24), but also Bacteria, preferably z. B.
- Shewanella, Vibrio or Moritella (Cho and Mo, Screening and characterization of eicosapentaenoic acid-producing marine bacteria, Biotechnology Letters 1999, 215-218; JP-A-2000/245442; JP-A-63-216490, JP-A -2001 / 309797).
- n-3 fatty acids is represented by transgenic organisms, preferably microorganisms and plants.
- n-3 active ingredients can be used in the sense of the invention, which are derived from oils as described above (e.g. fish oils, vegetable oils or oils from microorganisms) by various methods known to the person skilled in the art (e.g. chromatography, absorption or adsorption processes) , Winterization etc.) are cleaned up or concentrated on.
- Cholesterol-lowering active substances in the sense of the invention are understood to be active substances which can lower an elevated cholesterol level (> 200 mg / dl), in particular LDL cholesterol levels> 130 mg / dl. These are characterized by the fact that they specifically influence certain metabolic processes and thus lead to a secondary reduction in LDL cholesterol and total cholesterol (usually between 10-55%).
- the active substances in the context of the invention include cholesterol-lowering substances from the group of statins, bile acid absorption inhibitors and bile acid sequestrants, cholesterol absorption inhibitors, fibrates, nicotinic acid derivatives, but also the group of phytosterols and plant levels and cholesterol-lowering plant extracts.
- lovastatin [s. Fig. 1 below] (e.g. US-A-4,231,938), Paravastatin (e.g. US-A-4,346,227), Simvastatin [s. Fig. 2 below] (e.g. US-A 4,444,784), fluvastatin (e.g. US-A-5,354,772), atorvastatin (e.g. US-A-5,273,995) or cerivaststatin (e.g. US A-5, 177,080) understood that act specifically by inhibiting cholesterol synthesis (HMG CoA reductase inhibitors) in the liver.
- HMG CoA reductase inhibitors HMG CoA reductase inhibitors
- Fig. 1 Lovastatin
- Fig. 2 Simvastatin
- Inhibitors of bile acid absorption in the sense of the invention are understood to mean substances which prevent the reuptake of bile acids in the intestine / ileum via a receptor-mediated process.
- These are in particular benzothiazepine derivatives (for example US Pat. No. 5,998,400, US Pat. No. 6,277,831), benzothiepin-1,1-dioxide derivatives (for example US Pat. No. 6,221,897, WO-A- 97/33882), in particular compounds according to Figures 3 and 4 below, which specifically block the bile acid reabsorption in the intestine, in particular in the ileum.
- Bile acid sequestrants act as polymeric ion exchange resins in the intestine, specifically on bile acids, but also on cholesterol, and lead to an increased excretion of the substances mentioned.
- This group of active ingredients includes a. Cholestyramine, colestipol or colesevlam hydrochloride. The two compounds mentioned are distinguished by a significantly weaker activity than statins or inhibitors of bile acid absorption.
- Cholesterol absorption inhibitors are active substances that inhibit the receptor-mediated transport of cholesterol in the intestine and thus increase the excretion of cholesterol, which ultimately leads to a moderate decrease in serum cholesterol levels. These include, in particular, hydroxy-substituted ones Group 1 Azetidinone Cholesterol Absorption Inhibitors - (4-fluorophenyl) -3 (R) - [3 (S) - (4-fluorophenyl) -3-hydroxypropyl)] - 4 (S) -4-hydroxyphenyl) -2-azetidinone ) and 1 - (4-fluorophenyl) -3 (R) - [3 (R) - (4-fluorophenyl) -3-hydroxypropyl)] - 4 (S) -4-hydroxyphenyl) -2-azetidinone) and their pharmacological effective salts or substituted ⁇ -lactam cholesterol absorption inhibitors (e.g. WO-A-95/35277
- the group of fibrates includes a. Clofibrate, etophylline clofibrate, bezafibrate, ciprofibrate, clinofibrate, binifibrate, lifibrol, fenofibrate, gemfibrozil or etofibrate.
- fibrates have a moderate lowering effect on LDL cholesterol with a slight improvement in HDL cholesterol values. Serum triglyderides are more affected by fibrates.
- Nicotinic acid derivatives in the sense of the invention are natural or synthetically produced nicotinic acid, its esters or synthetic derivatives such as, for. B. niceritrol, nicofuranose, ß-pyridylcarbinol or acipimox. This group of substances has a moderate effect on total and LDL cholesterol with improved HDL cholesterol levels.
- Phytosterols in the sense of the invention are understood to mean 4-demethylsterols, 4-monomethyl sterols and 4,4-dimethyl sterols and the respective esters as well as plant extracts, mixtures and foods rich in phytosterols. These include ß-sitosterol, campesterol, stigmatosterol, brassicasterol, desmosterol, chalinosterol, poriferasterol, clionasterol and all their natural or synthetic or isomeric derivatives.
- Vegetable stanols are understood to mean hydrogenated plant sterols such as, for example, B. Campestanol, Sitostanol and the respective esters as well as vegetable extracts, mixtures and foods rich in vegetable stanols.
- compositions with a cholesterol-lowering effect include artichoke extracts and extracts from garlic and guggulipid. They have long been used as natural remedies and show moderate effectiveness on total and LDL cholesterol levels.
- the agents according to the invention contain a carob product, in particular carob fiber, at least one cholesterol-lowering active ingredient and at least one n-3 fatty acid.
- the cholesterol-lowering agents can contain conventional additives such as solvents, fillers, carriers such as methyl cellulose, sweetening carbohydrates and other sweeteners, flavors, antioxidants and preservatives.
- the combination of a carob product, in particular carob fiber, with at least one n-3 fatty acid and at least one active ingredient can also be administered in the form of two or more different dosage forms.
- carob products in particular the carob fiber, and for the n-3 fatty acids.
- the direct addition of the carob product, in particular the carob fiber, and the n-3 fatty acids in foodstuffs produced in-house as well as use in the form of food supplements typical (e.g. tablets, dragees, hard or soft capsules, sachets, granules, bars, etc .) possible, while the active ingredients are administered rather in the manner typical of medicines (including tablets, coated tablets, hard or soft capsules, sachets, granules, etc.).
- the dietetic foods according to the invention contain the food components in amounts which are required for administration 2 to 4 times a day to achieve the therapeutic effect.
- the carob product or the carob fiber component is contained in the products according to the invention in concentrations which bring about a significant cholesterol reduction or influence the HDL ⁇ DL ratio in a positive manner.
- the daily dose of carob fiber can be in the range of 1-25 g, usually 5-15 g.
- n-3 fatty acids are contained in the products according to the invention in concentrations which, in synergy with the carob products described above, bring about a significant reduction in cholesterol and the HDL / LDL ratio in a positive manner
- the daily dose of n-3 fatty acids can be in the range of 50 mg to 10 g, usually from 100 mg to 5 g and preferably from 200 mg to 2 g.
- Locust bean product, in particular locust bean fiber, and n-3 fatty acids are used in these amounts in combination with the daily doses of the active ingredients if a particularly extensive reduction in the cholesterol level is desired.
- concentrations of active ingredients previously required for individual use the use concentrations can be reduced by up to 50-90% due to synergies.
- the additives which may be present can advantageously be added in concentrations of 1-90% by weight, in particular 10-60% by weight (based on the particular preparation form).
- the active ingredient combination according to the invention can be taken up at a specific time of day or distributed over the day, the quantitative ratios of active ingredient, locust bean product, in particular locust bean fiber, and n-3 fatty acid corresponding to the above-mentioned ratios when ingesting smaller doses.
- the procedure can preferably be such that the desired amounts of carob product, in particular carob fiber, n-3 fatty acids and active ingredient are mixed with one another, spray-dried, freed from the solvent, agglomerated and / or instantized.
- carob product in particular carob fiber, n-3 fatty acids and active ingredient
- all common food technology but also Gallic manufacturing processes such as pressing, kneading or coating can be used.
- the n-3 fatty acids can be added to the mixture in pure form or encapsulated or microencapsulated, it being possible to use all methods familiar to the person skilled in the art such as coacervation, spray drying or fluidized bed drying for the encapsulation or microencapsulation. Inclusion in liposomes or micelles is also possible.
- n-3 fatty acids can be added to the mixture in a form which provides a continuous (retarding) release of the fatty acids in the body allowed.
- Suitable processes for producing these slow release formulations are, for example, coating processes or the use of suitable capsule matrices in the (micro) encapsulation.
- the carob product in particular the carob fiber, can itself be used as a carrier or matrix for the n-3 fatty acids.
- locust bean products in particular locust bean fiber, n-3 fatty acids and cholesterol-lowering active ingredients
- the addition of locust bean products, in particular locust bean fiber, and n-3 fatty acids to the active ingredients does not reduce the activity of the active ingredients through non-specific interference, but that the effects observed go far beyond those achievable with individual administration of the three groups of substances ,
- the agents according to the invention thus make it possible to achieve a therapeutically often desirable, stronger lowering of the cholesterol level than previously or to achieve effects in a comparable amount as before, but with lower amounts of active ingredient.
- undesirable side effects, which frequently occur during the administration of cholesterol-lowering active ingredients, can thus be reduced or avoided entirely.
- the combination of active substances according to the invention thus represents a significant advance in drug therapy for hypercholesterolemia or hyperlipidemia.
- the active compound combinations according to the invention are expediently used in a suitable preparation which is coordinated with the most effective quantitative ratios.
- These preparations can also contain other ingredients (additives) to improve resolution such as soluble Carriers, tablet disintegrants such.
- sweeteners such as sucrose, glucose, fructose and other carbohydrates, sugar alcohols such as.
- sorbitol, xylitol, maltitol and isomalt or sweeteners such as.
- the agents according to the invention can also be administered separately in the form of a pharmaceutical preparation of the active ingredient and in the form of a food or food supplement containing the carob product, in particular carob fiber, and the n-3 fatty acids.
- the carob product in particular the carob fiber
- the carob product can be used as a carrier of the n-3 fatty acids.
- the separate administration of two foods or nutritional supplements is possible, one food or nutritional supplement containing the carob product and the other containing the n-3 fatty acid (s).
- the common pharmaceutical dosage forms such as tablets, capsules, solutions for ingestion as drops or powdered preparation or granules to be dissolved are suitable for the active ingredient.
- any food into which the carob product and the n-3 fatty acid can be incorporated is basically suitable as a food, with limits arising from the properties of the food component and the intended use. Accordingly, cereal-based foods such as baked goods, cereals, snack bars and fruit bars, desserts, special diet preparations such as beverages and in particular powdered drinks based on milk, fruit concentrates or powders, carbohydrates or sugar alcohols would be particularly suitable. With phytosterols and plant stanols, fatty foods such as B. vegetable spreads, dressings and dairy products.
- Powdered preparation (for one serving size)
- Lovastatin MSD Sharp and Dome GmbH, D-85540 Haar
- carob fiber Caromax ® , Nutrinova, Frankfurt
- DHA-rich algae oil (DHA content 43 area% of TFA; Nutrinova, Frankfurt) 150 mg xanthan (stabilizer) 150 mg
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003293967A AU2003293967A1 (en) | 2002-12-24 | 2003-12-22 | Cholesterol-reducing agent containing an n-3 fatty acid |
EP03789380A EP1581240A1 (de) | 2002-12-24 | 2003-12-22 | Cholesterinsenkendes mittel, enthaltend eine n-3-fettsäure |
US10/539,174 US20070166413A1 (en) | 2002-12-24 | 2003-12-22 | Cholestrol-reducing agent containing an n-3 fatty acid |
JP2004562815A JP2006514040A (ja) | 2002-12-24 | 2003-12-22 | n−3脂肪酸を含むコレステロール低下剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10261067A DE10261067A1 (de) | 2002-12-24 | 2002-12-24 | Cholesterinsenkendes Mittel, enthaltend eine n-3-Fettsäure |
DE10261067.3 | 2002-12-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004058281A1 true WO2004058281A1 (de) | 2004-07-15 |
Family
ID=32667548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/014713 WO2004058281A1 (de) | 2002-12-24 | 2003-12-22 | Cholesterinsenkendes mittel, enthaltend eine n-3-fettsäure |
Country Status (6)
Country | Link |
---|---|
US (1) | US20070166413A1 (de) |
EP (1) | EP1581240A1 (de) |
JP (1) | JP2006514040A (de) |
AU (1) | AU2003293967A1 (de) |
DE (1) | DE10261067A1 (de) |
WO (1) | WO2004058281A1 (de) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1830830A2 (de) * | 2004-12-06 | 2007-09-12 | Reliant Pharmaceuticals, Inc. | Omega-3-fettsäuren und dyslipidämisches mittel für die lipidtherapie |
WO2007132888A1 (ja) * | 2006-05-16 | 2007-11-22 | National Institute Of Advanced Industrial Science And Technology | 平滑筋収縮抑制剤 |
EP1922065A2 (de) * | 2005-08-04 | 2008-05-21 | Transform Pharmaceuticals, Inc. | Neue formulierungen mit fenofibrat und einem statin und relevante behandlungsverfahren |
JP2008516890A (ja) * | 2004-08-06 | 2008-05-22 | トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド | 新規なフェノフィブラート製剤および関連治療方法 |
JP2008524120A (ja) * | 2004-12-06 | 2008-07-10 | レリアント ファーマスーティカルズ インコーポレイテッド | オメガ−3脂肪酸類及びpparアゴニスト及び/又はアンタゴニスト並びにその併用製品を用いた治療 |
FR2912607A1 (fr) * | 2007-02-20 | 2008-08-22 | Gervais Danone Sa | Produit alimentaire semi-fluide comprenant des fibres de beta-glucane et de la gomme de guar, utilisation en tant qu'aliment fonctionnel |
WO2007011886A3 (en) * | 2005-07-18 | 2008-10-30 | Reliant Pharmaceuticals Inc | Treatment with azetidinone-based cholesterol absorption inhibitors and omega-3 fatty acids and a combination product thereof |
ITFI20080243A1 (it) * | 2008-12-15 | 2010-06-16 | Valpharma Sa | Formulazioni per la somministrazione orale di acidi grassi omega polienoici in combinazione con statine di origine naturale o semi-sintetica. |
EP3095782A1 (de) | 2015-05-18 | 2016-11-23 | Esteve Química, S.A. | Neues verfahren zur herstellung von 3-(4-methyl-1h-imidazol-1-yl)-5-(trifluormethyl)benzenamin |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
JP2012041283A (ja) * | 2010-08-17 | 2012-03-01 | Porien Project Kk | 血管新生抑制剤 |
US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
US8952000B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
US8951514B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
US9119826B2 (en) | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
US10123986B2 (en) | 2012-12-24 | 2018-11-13 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
US9629820B2 (en) | 2012-12-24 | 2017-04-25 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
CN104938816A (zh) * | 2015-06-02 | 2015-09-30 | 广西壮族自治区水牛研究所 | 一种能降低水牛机体胆固醇的饲粮 |
CN104982713A (zh) * | 2015-06-15 | 2015-10-21 | 广西壮族自治区水牛研究所 | 一种能提高水牛机体高密度脂蛋白胆固醇的饲粮 |
WO2017158132A1 (en) * | 2016-03-16 | 2017-09-21 | Dsm Ip Assets B.V. | Microbial production of nicotinic acid riboside |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6261925A (ja) * | 1985-09-10 | 1987-03-18 | Riken Kagaku Kogyo Kk | 脂質代謝促進剤 |
EP0616780A2 (de) * | 1993-03-26 | 1994-09-28 | Compania General Del Algarrobo De Espana, S.A. | Natürliche Johannisbrotfaser und Verfahren zur Herstellung derselben |
EP1203535A1 (de) * | 1999-07-16 | 2002-05-08 | Universitat de les Illes Balears | Verwendung von saatmehl verschiedener getreidesorten zur herstellung von lebensmittelprodukten geeignet zur behandlung von phytatmangelzustaenden |
WO2002043659A2 (en) * | 2000-11-29 | 2002-06-06 | Smithkline Beecham Corporation | Composition containing statins and calcium for improved cardiovascular health |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4027009A (en) * | 1973-06-11 | 1977-05-31 | Merck & Co., Inc. | Compositions and methods for depressing blood serum cholesterol |
US4231938A (en) * | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
MX7065E (es) * | 1980-06-06 | 1987-04-10 | Sankyo Co | Un procedimiento microbiologico para preparar derivados de ml-236b |
US5354772A (en) * | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
GB8819110D0 (en) * | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5177080A (en) * | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
GB9423172D0 (en) * | 1994-11-17 | 1995-01-04 | Wellcom Foundation The Limited | Hypolipidemic benzothiazepines |
IT1274355B (it) * | 1994-12-21 | 1997-07-17 | Alfa Wassermann Spa | Lattoni ad attivita' antiossidante ed ipolipidemica utili nella terapia dell'aterosclerosi |
TW438587B (en) * | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
US6180660B1 (en) * | 1997-08-26 | 2001-01-30 | Merck & Co., Inc. | Cholesterol-lowering therapy |
US6087353A (en) * | 1998-05-15 | 2000-07-11 | Forbes Medi-Tech Inc. | Phytosterol compositions and use thereof in foods, beverages, pharmaceuticals, nutraceuticals and the like |
US6221897B1 (en) * | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
DE19916108C1 (de) * | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
DE10147156A1 (de) * | 2001-09-25 | 2003-04-24 | Nutrinova Gmbh | Verkapselte Johannisbrotfasern mit verbesserten Produkteigenschaften, Verfahren zu ihrer Herstellung und ihre Anwendung |
DE20219667U1 (de) * | 2002-12-19 | 2003-02-27 | Beisel Guenther | Zubereitung zur Appetitminderung, Sättigung und/oder Gewichtsreduktion für Kinder |
-
2002
- 2002-12-24 DE DE10261067A patent/DE10261067A1/de not_active Withdrawn
-
2003
- 2003-12-22 US US10/539,174 patent/US20070166413A1/en not_active Abandoned
- 2003-12-22 EP EP03789380A patent/EP1581240A1/de not_active Withdrawn
- 2003-12-22 WO PCT/EP2003/014713 patent/WO2004058281A1/de not_active Application Discontinuation
- 2003-12-22 AU AU2003293967A patent/AU2003293967A1/en not_active Abandoned
- 2003-12-22 JP JP2004562815A patent/JP2006514040A/ja not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6261925A (ja) * | 1985-09-10 | 1987-03-18 | Riken Kagaku Kogyo Kk | 脂質代謝促進剤 |
EP0616780A2 (de) * | 1993-03-26 | 1994-09-28 | Compania General Del Algarrobo De Espana, S.A. | Natürliche Johannisbrotfaser und Verfahren zur Herstellung derselben |
EP1203535A1 (de) * | 1999-07-16 | 2002-05-08 | Universitat de les Illes Balears | Verwendung von saatmehl verschiedener getreidesorten zur herstellung von lebensmittelprodukten geeignet zur behandlung von phytatmangelzustaenden |
WO2002043659A2 (en) * | 2000-11-29 | 2002-06-06 | Smithkline Beecham Corporation | Composition containing statins and calcium for improved cardiovascular health |
Non-Patent Citations (4)
Title |
---|
DATABASE WPI Section Ch Week 198717, Derwent World Patents Index; Class B04, AN 1987-118804, XP002276669 * |
DREXEL H ET AL: "[Therapy of hyperlipoproteinemia]", SCHWEIZERISCHE RUNDSCHAU FUR MEDIZIN PRAXIS = REVUE SUISSE DE MEDECINE PRAXIS. SWITZERLAND 27 APR 1993, vol. 82, no. 17, 27 April 1993 (1993-04-27), pages 506 - 509, XP009028411, ISSN: 1013-2058 * |
FARMER J A ET AL: "Choosing the right lipid-regulating agent: A guide to selection", DRUGS 1996 NEW ZEALAND, vol. 52, no. 5, 1996, pages 649 - 661, XP009028410, ISSN: 0012-6667 * |
ST-ONGE MARIE-PIERRE ET AL: "Consumption of a diet containing medium chain triglycerides, phytosterols and flaxseed oil for 28 d decreases blood lipid parameters compared to a diet containing olive oil", FASEB JOURNAL, vol. 16, no. 4, 20 March 2002 (2002-03-20), Annual Meeting of the Professional Research Scientists on Experimental Biology;New Orleans, Louisiana, USA; April 20-24, 2002, pages A636, XP009028412, ISSN: 0892-6638 * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008516890A (ja) * | 2004-08-06 | 2008-05-22 | トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド | 新規なフェノフィブラート製剤および関連治療方法 |
JP2008524120A (ja) * | 2004-12-06 | 2008-07-10 | レリアント ファーマスーティカルズ インコーポレイテッド | オメガ−3脂肪酸類及びpparアゴニスト及び/又はアンタゴニスト並びにその併用製品を用いた治療 |
EP1830830A4 (de) * | 2004-12-06 | 2010-02-10 | Reliant Pharmaceuticals Inc | Omega-3-fettsäuren und dyslipidämisches mittel für die lipidtherapie |
EP1830830A2 (de) * | 2004-12-06 | 2007-09-12 | Reliant Pharmaceuticals, Inc. | Omega-3-fettsäuren und dyslipidämisches mittel für die lipidtherapie |
JP2008522970A (ja) * | 2004-12-06 | 2008-07-03 | レリアント ファーマスーティカルズ インコーポレイテッド | 脂質療法用のオメガ−3脂肪酸類及び異常脂質血症薬剤 |
WO2007011886A3 (en) * | 2005-07-18 | 2008-10-30 | Reliant Pharmaceuticals Inc | Treatment with azetidinone-based cholesterol absorption inhibitors and omega-3 fatty acids and a combination product thereof |
EP1922065A2 (de) * | 2005-08-04 | 2008-05-21 | Transform Pharmaceuticals, Inc. | Neue formulierungen mit fenofibrat und einem statin und relevante behandlungsverfahren |
EP1922065A4 (de) * | 2005-08-04 | 2009-11-11 | Transform Pharmaceuticals Inc | Neue formulierungen mit fenofibrat und einem statin und relevante behandlungsverfahren |
US7772277B2 (en) | 2005-08-04 | 2010-08-10 | Transform Pharmaceuticals, Inc. | Formulations comprising fenofibrate and a statin, and related methods of treatment |
WO2007132888A1 (ja) * | 2006-05-16 | 2007-11-22 | National Institute Of Advanced Industrial Science And Technology | 平滑筋収縮抑制剤 |
JP5158715B2 (ja) * | 2006-05-16 | 2013-03-06 | 独立行政法人産業技術総合研究所 | 平滑筋収縮抑制剤 |
FR2912607A1 (fr) * | 2007-02-20 | 2008-08-22 | Gervais Danone Sa | Produit alimentaire semi-fluide comprenant des fibres de beta-glucane et de la gomme de guar, utilisation en tant qu'aliment fonctionnel |
WO2008101929A1 (fr) * | 2007-02-20 | 2008-08-28 | Compagnie Gervais Danone | Produit alimentaire semi-fluide comprenant des fibres de beta-glucane et de la gomme de guar, utilisation en tant qu'aliment fonctionnel |
ITFI20080243A1 (it) * | 2008-12-15 | 2010-06-16 | Valpharma Sa | Formulazioni per la somministrazione orale di acidi grassi omega polienoici in combinazione con statine di origine naturale o semi-sintetica. |
WO2010069951A1 (en) * | 2008-12-15 | 2010-06-24 | Valpharma S.A. | Oral formulations comprising omega polyenoic fatty acids in combination with natural or semi -synthetic statins |
EP3095782A1 (de) | 2015-05-18 | 2016-11-23 | Esteve Química, S.A. | Neues verfahren zur herstellung von 3-(4-methyl-1h-imidazol-1-yl)-5-(trifluormethyl)benzenamin |
Also Published As
Publication number | Publication date |
---|---|
US20070166413A1 (en) | 2007-07-19 |
AU2003293967A1 (en) | 2004-07-22 |
JP2006514040A (ja) | 2006-04-27 |
DE10261067A1 (de) | 2004-08-05 |
EP1581240A1 (de) | 2005-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004058281A1 (de) | Cholesterinsenkendes mittel, enthaltend eine n-3-fettsäure | |
DE60210465T2 (de) | Verstärktes reiskleie-nahrungsmittelprodukt zur unterstützung der gesundheit von herz und kreislauf | |
DE69912833T2 (de) | Zusammensetzung enthaltend sojaprotein, diätfasern und phytoestrogen sowie ihre verwendung zur vorbeugung und/oder behandlung von kardiovaskulären erkrankungen | |
DE60207877T2 (de) | Zusammensetzung enthaltend Procyanidine zur Verminderung des Appetits bei Säugetieren | |
DE60104450T2 (de) | Chrom enthaltende zusammensetzung zur behandlung von diabetes, zur verbesserung der insulinsensitivität und zur reduktion von hyperglykämie, hypercholesterolämie und des körperfettanteils | |
WO2004105516A1 (de) | Diätetische lebensmittel bei einer gewichtskontrollierenden bzw. gewichtsreduzierenden ernährung | |
WO1999033355A2 (de) | Fettmischung | |
EP1983989A1 (de) | Kombinationen aus botanischen extrakten zur förderung der kardiovaskulären gesundheit | |
WO2004057979A2 (de) | Diätetisches lebensmittel zur positiven beeinflussung der kardiovaskulären gesundheit enthaltend johannisbrotprodukt und omega-3-fettssäure | |
EP1091659B1 (de) | Orale darreichungsform | |
WO2005023271A1 (de) | Physiologisch aktive zusammensetzung auf phosphatidylserin-basis | |
EP1526857A1 (de) | Cholesterinsenkendes mittel aus ballaststoffen und cholesterinsenkenden stoffen | |
WO2010072209A2 (de) | Nahrungsergänzungsmittel auf der basis von pantothensäure | |
US7695744B1 (en) | Natural supplement of cholesterol lowering oil seeds and nuts and method of manufacture | |
EP1529524B1 (de) | Gelatinekapsel mit fettlöslichen Vitaminen und essentiellen Fettsäuren | |
DE10233342A1 (de) | Cholesterinsenkendes Mittel | |
WO2019012137A1 (de) | Kombination aus propionsäure/buttersäure und fingolimod zur anwendung bei der behandlung von multipler sklerose | |
DE60034141T2 (de) | Lebensmittelzusammensetzungen sowie verfahren zur herstellung derselben | |
LU501504B1 (de) | Pulverförmiges nahrungsergänzungsmittel zur herstellung eines getränks | |
DE19633446B4 (de) | Arzneimittel mit lipidsenkender Wirkung | |
DE10303900A1 (de) | Cholesterinsenkendes Mittel, enthaltend Levane | |
DE10320983A1 (de) | Cholesterinsenkendes Mittel aus Ballaststoffen und cholesterinsenkenden Stoffen, insbesondere Guglipid bzw. Sojaprotein | |
EP4248956A2 (de) | Pharmazeutische zusammensetzung mit cannabidiol | |
DE202007014795U1 (de) | Mikronährstoffpräparat, insbesondere geeignet für die nutritive Ergänzung zur Migräne-Prophylaxe | |
DE202006010771U1 (de) | Mikronährstoffpräparat, insbesondere geeignet für die nutritive Ergänzung zur Migräne-Prophylaxe |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007166413 Country of ref document: US Ref document number: 10539174 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003789380 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004562815 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003789380 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10539174 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003789380 Country of ref document: EP |